Now that there s agreement to invest in innovation, let s make it meaningful Nancy Yates, Chief Nursing Informatics Officer, Providence St. Joseph Health and Michelle Woodley, Chief Nursing Informatics Officer, Providence St. Joseph Health
Nancy Yates, Chief Nursing Informatics Officer, Providence St. Joseph Health
Healthcare digital innovation has hit a milestone. No longer are executives questioning “if” they should invest. In fact, in a recent study, more than 75 percent of healthcare executives said digital innovation is key to their long-term strategy. The question now is, “How?”
In a period of policy and financial uncertainty, how do we ensure we have the capacity to make necessary investments? And, perhaps most importantly, how do we ensure investments are clearly meaningful assets to our organization and will truly make a difference in the lives of those we touch?
Share:
ProPath, the largest fully physician-owned pathology practice in the United States, today announced that Julia A. Bridge, M.D., a board-certified pathologist and geneticist with an extensive medical career and expertise in solid tumor molecular testing, has joined the ProPath team.
Dr. Bridge, who recently directed the Molecular Pathology Research Division at the Translational Genomics Research Institute in Phoenix, AZ, will be directing ProPath s fluorescence in situ hybridization (FISH) and cytogenetics team. She will also be incorporating her testing expertise in bone/soft tissue tumors for ProPath s molecular pathology team. We are thrilled to have Dr. Bridge join our team, said Cory A. Roberts, M.D., President, Chairman and CEO of ProPath. She has a rare combination of expertise in both anatomic pathology and cytogenetics that make her an expert with an international consultative practice. Her ability to interpret microscopic morphology in concert with her unsurpass
This lab is helping fight the STI testing shortage caused by COVID-19
Share Article
MicroGenDX is a PCR and NGS lab with its own lab developed test (LDT) and is not impacted by the same shortages that are causing delays in STI testing elsewhere.
MicroGenDX Logo
MicroGenDX has over 11 years’ experience designing, and validating laboratory developed tests and mitigating risk in supply chains so that we are able to run the test you need when you need it. ORLANDO, Fla. (PRWEB) December 21, 2020 In an era when shortages abound, having options is invaluable. Worldwide, labs are facing a scarcity of supplies, as those needed to test for diseases such as sexually transmitted infections (STIs) must be diverted to Covid-19 testing. Enter MicroGenDX, a company specializing in qPCR + Next Generation Sequencing (NGS) microbial molecular diagnostics.a company that designs and set up its own tests and multiplex panels in-ho